TABLE 3

Association between blood peak intensity of five key sphingolipid metabolites and vitamin D intervention in VDAART children stratified by 17q21 genotype

	Age 1 year^#		Age 3 years^¶		All samples⁺
	Coefficient (95% CI)	p-value	Coefficient (95% CI)	p-value	Coefficient (95% CI)	p-value
Sphinganine-1-phosphate
CC	−0.016 (−0.073–0.002)	0.065	0.001 (−0.044–0.051)	0.895	−0.015 (−0.048–0.017)	0.350
GC	0.003 (−0.019–0.034)	0.580	0.004 (−0.026–0.043)	0.635	0.007 (−0.016–0.029)	0.548
GG	0.016 (−0.013–0.086)	0.147	0.017 (−0.014–0.094)	0.149	0.040 (0.002–0.078)	0.038^§
Sphinganine
CC	−0.004 (−0.072–0.052)	0.752	0.006 (−0.067–0.094)	0.744	0.001 (−0.052– 0.053)	0.982
GC	0.010 (−0.023–0.067)	0.334	−0.007 (−0.073–0.043)	0.608	0.005 (0.032– 0.042)	0.787
GG	0.013 (−0.079–0.141)	0.586	0.041 (−0.002–0.193)	0.059	0.065 (−0.011–0.141)	0.091
Sphingosine-1-phosphate
CC	−0.009 (−0.039–0)	0.054	−0.001 (−0.032–0.027)	0.872	−0.012 (−0.031–0.007)	0.212
GC	−4.6E-04 (−0.017–0.015)	0.898	0.003 (−0.016–0.028)	0.610	0.002 (−0.012– 0.016)	0.776
GG	0.006 (−0.015–0.042)	0.352	0.015 (0.005–0.065)	0.027^§	0.022 (0.001– 0.044)	0.038^§
Sphingosine
CC	−0.009 (−0.077–0.037)	0.486	0.005 (−0.059–0.084)	0.733	−0.005 (−0.052–0.041)	0.821
GC	0.010 (−0.019–0.065)	0.284	−0.006 (−0.07–0.04)	0.599	0.006 (−0.029–0.041)	0.736
GG	0.009 (−0.077–0.118)	0.679	0.043 (0.015–0.185)	0.024^§	0.057 (−0.01–0.124)	0.094
Phosphoethanolamine
CC	−0.009 (−0.069–0.027)	0.389	0.015 (−0.006–0.074)	0.096	0.003 (−0.032–0.038)	0.870
GC	−0.011 (−0.06–0.008)	0.142	−0.009 (−0.054–0.014)	0.251	−0.021 (−0.047–0.005)	0.120
GG	0.020 (−0.016–0.108)	0.152	0.018 (−0.005–0.086)	0.086	0.038 (−0.003–0.08)	0.071

VDAART: Vitamin D Antenatal Asthma Reduction Trial. ^#: CC n=112 (27%), GC n=221 (54%), GG n=80 (19%); ^¶: CC n=106 (30%), GC n=172 (49%), GG n=75 (21%); ⁺: all samples combined according to a mixed model, CC n=218 (28%), GC n=393 (51%), GG n=155 (20%); ^§: significant at the 95% confidence interval.